RLRaija Lithovius

Raija Lithovius

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raija Lithovius has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Depression is associated with lower adherence to cardioprotective medications in adults with type 1 diabetes

    by Raija Lithovius, Stefan Mutter, Erika B. Parente, Valma Harjutsalo, Per-Henrik Groop, Lena M. Thorn, Niina Sandholm

    Aims: To investigate the association between depression and refill adherence to cardioprotective medications in a representative cohort of type 1 diabetes adults. Methods: This Finnish Diabetic Nephropathy (FinnDiane) sub-study included 1,588 adults with type 1 diabetes who had purchased antihypertensive or lipid-lowering drugs within ± 0.5 years from study baseline. The proportion of days covered (PDC) method was used to calculate overall refill adherence over a 10-year follow-up. Adherence was classified into good (> 80%), intermediate (≥ 50 and < 80%), and poor (< 50%). Participants were considered to have depression, if they had a diagnosis of depression or had purchased antidepressive agents at any time point from 1995 until the end of follow-up, identified from national registries. Multinomial logistic regression analysis, adjusted for age, sex, duration of diabetes, education level, HbA 1c , BMI, diabetic kidney disease, smoking, and alcohol consumption was performed. Results: Of the cohort 37% had depression during the study period. Those individuals with depression were more often women ( P = 0.0001), and had lower adherence to cardioprotective medication ( P = 0.02) than those without depression. Individuals with depression had 72% higher odds ([95% CI 1.09, 2.70], P = 0.02) of having poor versus good adherence, compare to those without depression. The results persisted after excluding antidepressants potentially used for neuropathic pain (OR 1.61 [95% CI 1.02, 2.55], P = 0.04). Conclusions: Healthcare professionals should assess presence of depression and monitor medication adherence at regular consultations, and whenever needed, should implement strategies to manage the depression in order to enhance adherence, which might ultimately lead to improved cardiovascular outcomes in type 1 diabetes.

  • Open Access

    Lessons learned from the FinnDiane Study: Epidemiology and metabolic risk factors for diabetic kidney disease in type 1 diabetes

    by Fanny Jansson Sigfrids, Raija Lithovius, Per‐Henrik Groop, Lena M. Thorn

    Aims: Across its operational span of more than 25 years, the observational, nationwide, multicentre Finnish Diabetic Nephropathy (FinnDiane) Study has aimed to unravel mechanisms underlying diabetic kidney disease, with a special focus on its metabolic risk factors. We sought to compile key findings relating to this topic and to offer a current perspective on the natural course of diabetic kidney disease among individuals with type 1 diabetes.Methods: In this narrative review, articles relevant to the subject published by the FinnDiane Study were identified and summarized together with work published by others, when relevant.Results: The FinnDiane Study has underscored the significance of dysglycaemia and insulin resistance, increased visceral fat mass, hypertension and dyslipidaemia—particularly high triglycerides and remnant cholesterol—as risk factors for diabetic kidney disease. Factors like abdominal obesity seem to influence the early stages of the disease, while the presence of the metabolic syndrome becomes implicated at later stages. Epidemiological reports have revealed that after an initial decline, the cumulative incidence of albuminuria plateaued post‐1980s, with the progression rate to kidney failure remaining high. Fortunately, 23% of the FinnDiane cohort regressed to less advanced stages of albuminuria, improving their overall prognosis.Conclusion: A substantial burden of albuminuria associated with type 1 diabetes persists, and therefore, novel kidney‐protecting therapies are highly awaited. In addition, given that metabolic factors influence the progression of diabetic kidney disease both in its early and advanced stages, emphasis should be placed on ensuring that their treatment targets are met.


  • Open Access

    Adherence to cardio-protective medications and cardiovascular disease in adults with type 1 diabetes

    by Raija Lithovius, Stefan Mutter, Erika B. Parente, Valma Harjutsalo, Per-Henrik Groop


  • Open Access

    L-type calcium channel blocker increases VEGF concentrations in retinal cells and human serum

    by Anmol Kumar, Stefan Mutter, Erika B. Parente, Valma Harjutsalo, Raija Lithovius, Sinnakaruppan Mathavan, Carol Forsblom, Markku Lehto, Timo P. Hiltunen, Kimmo K. Kontula, et al.

    Objective: Vascular endothelial growth factor (VEGF) plays a key role in diabetic retinopathy (DR). L-type calcium channel blockers (LTCCBs) have been widely used as antihypertensive medication (AHM), but their association with VEGF and DR is still unclear. Therefore, we explored the effect of LTCCBs compared to other AHMs on VEGF concentrations in retinal cells and human serum. Furthermore, we evaluated the association between the use of LTCCBs and the risk of severe diabetic eye disease (SDED). Research design and methods: Müller cells (MIO-M1) were cultured as per recommended protocol and treated with LTCCBs and other AHMs. VEGF secreted from cells were collected at 24 hours intervals. In an interventional study, 39 individuals received LTCCBs or other AHM for four weeks with a four-week wash-out placebo period between treatments. VEGF was measured during the medication and placebo periods. Finally, we evaluated the risk of SDED associated with LTCCB usage in 192 individuals from the FinnDiane Study in an oberservational setting. Results: In the cell cultures, medium VEGF concentration increased time-dependently after amlodipine (p0.01), or lisinopril (p>0.01). Amlodipine, but no other AHM, increased serum VEGF concentration (p<0.05) during the interventional clinical study. The usage of LTCCB was not associated with the risk of SDED in the observational study. Conclusions: LTCCB increases VEGF concentrations in retinal cells and human serum. However, the usage of LTCCBs does not appear to be associated with SDED in adults with type 1 diabetes.